Clinical Efficacy of Induction Therapy Using Mycophenolate Mofetil for Diffuse Proliferative Lupus Nephritis

Wei Xin

Abstract：Objective To evaluate clinical efficacy and safety of treating diffuse proliferative lupus nephritis (LN)with mycophenolate mofetil(MMF). Methods 74 patients diagnosed as LN by renal biopsy were selected,clini-cal types of whom were type Ⅳ with formation of crescents(≥15% ). They were randomly assigned to control group and treatment group with 37 cases in each group. Intermittent intravenous cyclophosphamide(Ⅳ - CTX)and MMF in-duction therapy were used in two groups respectively. Remission rate differences were compared 6 months after induc-tion therapy. Serum immune indicators were measured and safety of medication was evaluated. Results Total remis-sion rate was higher in treatment group than that in control group after 6 months induction in 60 patients with crescents< 50%(P < 0. 05). There was no significant difference in total remission rate between treatment group and control group in 14 patients with crescents≥50%(P > 0. 05). C3 recovery rate was significantly better in treatment group than that in control group 6 months after induction(P < 0. 05). There was no significant difference in ds - DNA nega-tive conversion rate and complement C4 recovery rate between the two groups(P > 0. 05). There were no serious com-plications in the two groups during treatment. There were less patients with white blood cells reduction in treatment group than that in control group(P < 0. 05). Conclusion MMF induction treatment can promote remission rate and has less adverse reactions for patients with type Ⅳ LN with formation of crescents.